Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold
DeviceBioresorbable Drug-Eluting Scaffold Implantation for the Treatment of Coronary Artery Disease
NCT Number: NCT02539966
The FANTOM II trial is intended to assess safety and performance of the Fantom Bioresorbable Coronary Scaffold in native coronary arteries.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
The Prince Charles Hospital, Chermside, Australia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Bioresorbable Drug-Eluting Scaffold Implantation for the Treatment of Coronary Artery Disease
Time frame: 6 months
Cardiac Death, Myocardial Infarction (Q-Wave, Non Q-wave: CK-MB >5X ULN) (MI), and target lesion revascularization (TLR)
Time frame: 6 months
Late Lumen Loss
Time frame: 9 months
Late Lumen Loss
Time frame: 6 months
Minimum Lumen Diameter (MLD)
Time frame: 9 months
Minimum Lumen Diameter (MLD)
Time frame: 6 months
% Diameter Stenosis
Time frame: 9 months
% Diameter Stenosis
Time frame: 6 months
Binary Restenosis
Time frame: 9 months
Binary Restenosis
Time frame: 12, 24, 36, 48 and 60 months
Cardiac Death, Myocardial Infarction (Q-Wave, Non Q-wave: CK-MB >5X ULN) (MI), and target lesion revascularization (TLR)
Time frame: 12, 24, 36, 48 and 60 months
Percentage of patients with TLR at each time point
Time frame: 12, 24, 36, 48 and 60 months
Percentage of patients with TVR at each time point
Time frame: 12, 24, 36, 48 and 60 months
Percentage of patients with TVF at each time point
Time frame: Day 0
Successful acute delivery and deployment of the device
Time frame: 30 days
Percentage of patients with angiographic success (final diameter stenosis <50% without occurrence of MACE)
REVA Medical, Inc.
Industry
Acronym: FANTOM II
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03188705
Arterial Occlusive Diseases, Arteriosclerosis
Lancaster, Pennsylvania, United States
View Trial DetailsNCT07468955
Arterial Occlusive Diseases, Arteriosclerosis
Kütahya, Center, Turkey (Türkiye)
View Trial DetailsNCT06029517
Arterial Occlusive Diseases, Arteriosclerosis
Buffalo, New York, United States
View Trial DetailsNCT04058990
Arterial Occlusive Diseases, Arteriosclerosis
Kitakyushu, Fukuoka, Japan
View Trial Details